Author

Sakshi Agarwal

Agency for Science, Technology and ResearchPrimary ORCID profile (0000-0001-6383-8597 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Sakshi AgarwaliD1 paper · Institute of Medical Sciences

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:zebrafish· 1

Frequent Co-Authors

Amit SinghaliD· 1 shared Darryl JY HaniD· 1 shared Luke H. HoeppneriD· 1 shared Ria SorayahiD· 1 shared Stefan H. OehlersiD· 1 shared Xiangyu SuiiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

Amit SinghalORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

MicrobiologyBiomedicine & PharmacotherapyPeer-reviewedAug 12, 2025

The repurposed STAT3 inhibitor pyrimethamine controls mycobacterial infection-induced vascular permeability and mycobacterial burden

Darryl JY Han, Xiangyu Sui, Sakshi Agarwal…·Stefan H. Oehlers

The paper shows pyrimethamine, an FDA-approved drug, reduces vascular permeability and mycobacterial burden in a zebrafish infection model by inhibiting bacterial dihydrofolate reductase and restoring vascular barrier function.

3 citations

zebrafishexperimental assay

𝕏 PostBluesky